title: Comparing clinical outcomes for a twelve-month trial of zotarolimus- and everolimus-eluting stents in patients with coronary artery disease: data from the THCRIC registry.
abstract: OBJECTIVE
  New-generation coronary stents including zotarolimus- and everolimus-eluting stents (ZES and EES) have been shown to decrease the risk of restenosis. The purpose of this study was to compare the safety and efficacy of ZES and EES over a 12-month clinical follow up, in routine clinical practice.
  
  
  METHODS
  This is an observational study in which 1029 consecutive patients treated with ZES (n = 669) or EES (n = 360) were enrolled. The study endpoint was major adverse cardiac events (MACE), defined as cardiac death, nonfatal myocardial infarction (MI), and target lesion or vessel revascularization at 12 months.
  
  
  RESULTS
  Follow up was completed among 94.9% of the patients. The overall MACE occurred in 4 (0.6%) and 7 (2.0%) patients in the ZES and EES group, respectively. The occurrence of other cardiac events including nonfatal MI and target vessel or lesion revascularization was 1 (0.2%) versus 1 (0.3%) and 7 (1.1%) versus 5 (1.4%), respectively, in the ZES and EES groups of patients. Despite a slightly lower rate of MACE and cardiac death in the ZES group, the difference between these two groups was not significant (n = 0.064 for overall MACE, p = 0.129 for cardiac mortality, n = 0.999 for nonfatal MI, n = 0.468 for target vessel and n = 0.999 for target lesion revascularization).
  
  
  CONCLUSIONS
  According to our results, it could be concluded that the difference in the rate of MACE between the ZES and EES groups was not statistically significant at 12-month follow up.
authors: Interventional Cardiology Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
authors: Hamid Reza
authors: HR
authors: Poorhoseini
authors: Interventional Cardiology Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
authors: Seyed Ebrahim
authors: SE
authors: Kassaian
authors: Interventional Cardiology Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
authors: Kianoosh
authors: K
authors: Hoseini
authors: Clinical Research Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
authors: Sepideh
authors: S
authors: Saroukhani
authors: Interventional Cardiology Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
authors: Mojtaba
authors: M
authors: Salarifar
authors: Interventional Cardiology Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
authors: Mohammad
authors: M
authors: Alidoosti
authors: Interventional Cardiology Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
authors: Ebrahim
authors: E
authors: Nematipour
authors: Interventional Cardiology Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
authors: Ali Mohammad
authors: AM
authors: Haji-Zeinali
authors: Interventional Cardiology Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
authors: Alireza
authors: A
authors: Amirzadegan
authors: Associate Professor of Interventional Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, North Kargar Street, PO Box: 1411713138, Tehran, Iran mohammadzad@gmail.com.
authors: Mir Hossein
authors: MH
authors: Seyyed Mohammadzadeh
authors: Cardiology Department, Urmia University of Medical Sciences, Urmia, Iran.
authors: Kamal
authors: K
authors: Khadem Vatan
authors: Interventional Cardiology Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
authors: Hassan
authors: H
authors: Aghajani
authors: Clinical Research Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
authors: Mahmood
authors: M
authors: Sheikh Fathollahi
authors: Reproductive Health Research Center, Urmia University of Medical Sciences, Urmia, Iran.
authors: Hamidreza
authors: H
authors: Farrokh-Eslamlou
mesh_terms: D000368:Aged; D003324:Coronary Artery Disease / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D000068338:Everolimus / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects* / Q000706:statistics & numerical data; D012042:Registries; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D000068338:Everolimus; C489443:zotarolimus; D020123:Sirolimus
keywords: coronary artery diseases; revascularization; stents